Imagion Biosystems has announced and amendment to the proposed timetable for the Pro-Rata Renounceable Rights Issue as announced on Monday, 28 October 2019.
Read the amended timetable.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance